Takeda expands Phase III ixazomib MM program to Japan
This article was originally published in Scrip
Takeda has begun enrolling the first patients in Japan into the ongoing TOURMALINE-MM1 Phase III global study with potential Velcade successor ixazomib citrate (MLN9708), to generate data in support of a planned approval filing in the country.
You may also be interested in...
While it has raised the full-year profit outlook, Takeda came in under analysts' consensus for some of its fiscal first-half figures, pointing to a growing forex impact.
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.